Telix Pharmaceuticals and Regeneron Pharmaceuticals say they will work together to make and sell new radiopharmaceutical medicines.
Telix will bring its experience in making radiopharmaceuticals, global factories, and supply chains. Regeneron will bring its knowledge of biologic medicines, including special antibodies. They will focus on several types of solid tumors and also plan to make radio-diagnostics to help choose patients and check how treatments are working.
Regeneron will pay Telix USD 40 million to use its manufacturing for four initial programs. Regeneron can choose to add four more programs with more payments. Telix and Regeneron will share costs and profits from selling the medicines. Telix can also help promote some products. If Telix does not join a program, it can still get up to USD 535 million in milestone payments and small royalties from future sales.
According to coherent market insights, the Pharmaceutical Market is expected to grow at a CAGR of 8.3% during 2026 to 2033. Currently, the market is at USD 1.96 Tn in 2026 and is expected to be around USD 3.43 Tn by 2033. This significant growth trajectory is driven by the rising healthcare demands, advancements in drug development, and increasing investments in biopharmaceutical research worldwide, positioning the market for robust expansion over the forecast period.
"At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities – from monoclonal and bispecific antibodies to cell therapies and beyond. Targeted Biotechnology represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need," said John Lin, M.D., Ph.D., Senior Vice President of Oncology & Antibody Technology Research at Regeneron.
"Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron's antibody technologies and oncology portfolio," said Israel Lowy, M.D., Ph.D., Senior Vice President, Clinical Development Unit Head, Oncology at Regeneron. "Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care."
"The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients," said Christian Behrenbruch, D.Phil., Managing Director and Group CEO at Telix. "We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers."
Source:
Newsroom: Telix Pharmaceuticals
Company: Telix Pharmaceuticals
